AI-generated · cited to primary sources · not investment advice
Alpex Solar (ALPEXSOLAR) Aug 2026 Filing Analysis
Does management do what it says?
The target has not yet been achieved. Q3 FY26 EBITDA margin was 14.03%, and management only stated that margins should expand rapidly once cell manufacturing starts. The cell line was expected to start around Q1 FY27. (4 in progress across 4 tracked commitments)
“since our cell is almost there, so, for Alpex, we don't see any pressure on the margins in the short or in the long run. So, we will continue enjoying the better margins than the industry.”
See the full cited Management analysis of Alpex Solar
How durable is the business?
Module manufacturing remained the core business, but management described the business as expanding sharply in volume. H1 FY26 business volume was stated to be approximately 270%-300% higher, while module capacity was being expanded by 1.2 GW and another 1.2 GW was planned. Compared with the Aug 2026 baseline, modules remain the primary revenue stream, although competition is creating margin pressure. (5 expanding across 1 engine)
“solar module manufacturing being our primary revenue driver ... Our 2.4 gigawatt and soon to be 3.6 gigawatt module lines”
The company's integration moat strengthened materially. In Nov 2025, Alpex was moving from module manufacturing toward cells, aluminium frames, EPC and joint ventures for junction boxes. By Aug 2026, the baseline describes module, planned cell and aluminium-frame operations as an established integration strategy, with the advantage strengthening as facilities are commissioned. (5 expanding across 4 engines)
“we are producing aluminum frame in the facility, and we are likely to expand the capacity to 18,000 tons per annum. ... standalone basis this unit is also contributing towards the profitability of the company.”
The module business was still the core engine in H1 FY26 and grew substantially year over year. Consolidated revenue rose from Rs. 265.12 crore in H1 FY25 to Rs. 903.24 crore in H1 FY26, while EBITDA margin improved from 13.67% to 16.01%. This indicates both strong volume/revenue growth and better operating profitability, although the later baseline notes that the module market is becoming more competitive. (1 expanding, 3 new, 1 shifted across 1 engine)
“the cell business nowadays commands an EBITDA of around 35% to 40% and PAT of 20% to 25%. And there is still ample demand in the market and we don't see these margins going down substantially. And we hope to maintain at least for one year this kind of EBITDA or the PAT margins”
See the full cited Business Model analysis of Alpex Solar
Where does growth come from?
Module capacity is expanding in clear, staged increments: 1.2 GW capacity was established by FY23-25, 2.4 GW is targeted for FY26 and 3.6 GW by FY27. This represents a 3x increase from the 1.2 GW base over roughly two years. The latest planned step-up remains positive and indicates accelerating capacity creation. (5 accelerating across 5 signals, 1 leading indicator)
“So, with respect to the selling potential, we will have almost six months of clear manufacturing time for 2.2 gigawatt. So, that means around 1 gigawatt of cell will be available for selling in the market. And the market has extremely high appetite for the solar cells. ... So, assuming that we do even 65% of that, that means we will be doing around Rs. 1,700 crore in the last, I mean in the H2.”
The Kusum business shows a strong year-on-year expansion plan: revenue increased from Rs. 223 Cr last year to a FY27 target of Rs. 500 Cr, while Rs. 350 Cr of orders are already being executed. The latest order position provides improving visibility, although actual FY27 revenue is not yet reported. (1 accelerating across 1 signal)
“Last year we did Rs. 223 crores and this year we had a target of Rs. 500 crores. We have already received orders of Rs. 350 crores, which we are executing and as soon as these tenders open, we hope to surpass that also.”
See the full cited Future Growth analysis of Alpex Solar
What could break the thesis?
In the older November 2025 period, management said ALMM List 2 was expected to become effective from June 2026 and would require module makers to use locally produced cells. This made the regulatory support important to the company's demand outlook. Compared with the August 2026 baseline, where the implementation was still described as expected only by end-2026, the policy timeline appears to have become less certain or later. Therefore, regulatory dependence has worsened. (5 intensifying, 5 high-severity)
“We spent almost Rs. 890 CR... as of now our total debt is on this is just Rs. 341 odd crores... it won't be more than Rs. 350 odd crores or maybe Rs. 360 odd crores the debt component on this cell line.”
Management projected blended company EBITDA margins above 29%-30% after cell production begins, compared with current module EBITDA margins of about 15%-16%. It also claimed TOPCon could provide roughly 2% higher profit at the PAT level than mono-PERC. These are forward estimates without demonstrated Alpex cell operating results, so the risk was already high. The August 2026 baseline still relied on estimated cell EBITDA margins of 35%-40%, meaning the margin promise remained unproven rather than being de-risked. (2 stable, 2 high-severity)
“The cell business nowadays commands an EBITDA of around 35% to 40% and PAT of 20% to 25%.”
See the full cited Risk analysis of Alpex Solar
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.